Sanofi US News

In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy

Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial

* Designation based on positive results from Part A of pivotal Phase 3 trial

BIVV001 is the first investigational factor VIII therapy independent of von Willebrand Factor and has the potential to transform replacement therapy for people with hemophilia A

- New data on investigational brain-penetrant BTK inhibitor tolebrutinib (SAR442168) further support its potential in modulating disabling inflammatory processes within the central nervous system

- Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines

Potential to be the first approved therapeutic for the treatment of Non-responsive Celiac Disease

* Further strengthens core R&D areas of autoimmune and allergic diseases

-Former Director of the Office of New Drugs at the FDA's Center for Drug Evaluation and Research, brings extensive regulatory expertise and experience to Provention-

- Completed commercial-scale drug substance PPQ campaign ahead of schedule, enabling the expected on-time completion of the rolling Biologics License Application (BLA) submission for teplizumab in Q4 2020 -

- Promising vaccine candidate selected by U.S. government’s Operation Warp Speed

- Nirsevimab reduced respiratory syncytial virus (RSV) lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent1

* New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines

* Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent